GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (FRA:4MNA) » Definitions » EPS (Diluted)

Minerva Neurosciences (FRA:4MNA) EPS (Diluted) : €-4.14 (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Minerva Neurosciences EPS (Diluted)?

Minerva Neurosciences's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-1.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-4.14.

Minerva Neurosciences's EPS (Basic) for the three months ended in Mar. 2024 was €-1.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-4.14.

Minerva Neurosciences's EPS without NRI for the three months ended in Mar. 2024 was €-1.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €-4.33.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Minerva Neurosciences EPS (Diluted) Historical Data

The historical data trend for Minerva Neurosciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences EPS (Diluted) Chart

Minerva Neurosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.32 0.33 -8.28 -5.67 -4.23

Minerva Neurosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.22 -1.03 -0.97 -1.10 -1.04

Competitive Comparison of Minerva Neurosciences's EPS (Diluted)

For the Biotechnology subindustry, Minerva Neurosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's PE Ratio falls into.



Minerva Neurosciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Minerva Neurosciences's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-27.515-0)/6.506
=-4.23

Minerva Neurosciences's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-7.883-0)/7.569
=-1.04

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minerva Neurosciences  (FRA:4MNA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Minerva Neurosciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences (FRA:4MNA) Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences (FRA:4MNA) Headlines

No Headlines